Lung diffusing capacity for nitric oxide and carbon monoxide in relation to morphological changes as assessed by computed tomography in patients with cystic fibrosis
© Dressel et al; licensee BioMed Central Ltd. 2009
Received: 02 June 2008
Accepted: 16 June 2009
Published: 16 June 2009
Due to large-scale destruction, changes in membrane diffusion (Dm) may occur in cystic fibrosis (CF), in correspondence to alterations observed by computed tomography (CT). Dm can be easily quantified via the diffusing capacity for nitric oxide (DLNO), as opposed to the conventional diffusing capacity for carbon monoxide (DLCO). We thus studied the relationship between DLNO as well as DLCO and a CF-specific CT score in patients with stable CF.
Simultaneous single-breath determinations of DLNO and DLCO were performed in 21 CF patients (mean ± SD age 35 ± 9 y, FEV1 66 ± 28%pred). Patients also underwent spirometry and bodyplethysmography. CT scans were evaluated via the Brody score and rank correlations (rS) with z-scores of functional measures were computed.
CT scores correlated best with DLNO (rS = -0.83; p < 0.001). Scores were also related to the volume-specific NO transfer coefficient (KNO; rS = -0.63; p < 0.01) and to DLCO (rS = -0.79; p < 0.001) but not KCO. Z-scores for DLNO were significantly lower than for DLCO (p < 0.001). Correlations with spirometric (e.g., FEV1, IVC) or bodyplethysmographic (e.g., SRaw, RV/TLC) indices were weaker than for DLNO or DLCO but most of them were also significant (p < 0.05 each).
In this cross sectional study in patients with CF, DLNO and DLCO reflected CT-morphological alterations of the lung better than other measures. Thus the combined diffusing capacity for NO and CO may play a future role for the non-invasive, functional assessment of structural alterations of the lung in CF.
Cystic fibrosis (CF) is characterized by the combined findings of bronchiectasis and parenchymal fibrosis, which may affect lung diffusing capacity. However, the results of studies focussing on the diffusing capacity for carbon monoxide (DLCO) in CF are largely contradictory, as a spectrum of elevated, decreased, or normal values has been reported [1, 2]. Recent data in children and adults suggest a slightly elevated DLCO in early CF and a reduction only in advanced disease [3–5]. Based on these findings, DLCO currently appears to play no role in CF assessment compared to spirometry or computed tomography (CT) .
The diffusing capacity for nitric oxide (DLNO) can be used to directly describe pulmonary membrane diffusing capacity (Dm), without interfering with pulmonary capillary blood volume (Vc). Diffusion properties of NO are similar to those of CO; however, its rate of reaction with red blood cells is much greater . DLNO primarily reflects Dm, whereas DLCO depends on both Dm and Vc . In combination with DLCO, Vc and Dm can be determined in a single maneuver, based on the equation for the serial connection of resistances [8, 9].
Thus, DLNO might be superior to DLCO for quantification of structural changes by purely functional means when morphological changes of gas transport compartments instead of changes in pulmonary blood volume are considered. The method of choice for the assessment of morphological changes in CF is thin-section CT , which also represents the gold standard for the diagnosis of bronchiectasis . Quantification of disease extent in patients with CF can be achieved using dedicated scoring systems focussing on different parameters, e.g. bronchiectasis, mucous plugging or bronchial wall thickening . Specifically, the CT scoring system developed by Brody et al. has been shown to be a robust and reproducible tool for the semiquantitative assessment of parenchymal and airway disease in CF patients .
The aim of our study was to correlate DLNO, DLCO and other pulmonary function analyses with the extent of disease on CT in order to further investigate the hypothesis that DLNO as a measure of Dm may accurately reflect morphological changes in patients with CF.
Adult patients with CF (n = 21) in whom thin-section CTs of the lungs were available were recruited from the Cystic Fibrosis Outpatient Unit during routine follow-up visits. Patients with a smoking history or with an interval of more than 3 years between CT scans and pulmonary function tests (PFT) were excluded from the study. During the time between the CT and the PFT the clinical status of the patients had been regularly monitored by specialists from the Cystic Fibrosis Outpatient unit, usually with 3 months intervals between visits. Patients were excluded if severe exacerbations were present when CT scans or PFTs were performed. They were also excluded if severe exacerbations were recorded during the time interval between CT and PFT. Any exacerbation resulting in one or more days of hospitalisation was defined as severe. The study was approved by the local Ethics Committee and all participants gave their written informed consent.
Simultaneous single-breath determinations of DLCO, DLNO and alveolar volume (VA), were performed with a Masterscreen PFT (Viasys/Jaeger, Höchberg, Germany) which uses electrochemical sensors at an inspiratory target concentration of 45 (± 5) ppm NO and a breath-hold time of 8 s . Patients were seated in upright position, wearing a nose clip. The final inspiratory gas (21% O2) was mixed from a gas containing 448 ppm NO in N2 (Linde, Unterschleiβheim, Germany), a mixture of 0.28% CO and 9.5% He in synthetic air (Viasys), and 100% oxygen and analyzed immediately before inhalation. Maneuvers were performed as described previously  and the device was calibrated at least daily. Hb was measured in the patients and DLCO was corrected to the standard Hb according to international guidelines . All measurements were performed threefold with an interval of approx. 4 min, and mean values were recorded. Values relative to volume (KNO, KCO) were obtained by dividing DLNO and DLCO through the corresponding VA. VA, DLNO and DLCO %predicted were calculated using published reference formulae [15–19]. Using a standard approach Dm was expressed as DLNO divided by 1.97 , and Vc was derived as previously described .
Spirometry and bodyplethysmography were performed using a pneumotachograph-based device (MasterLab™, Viasys) following established guidelines . At least three technically acceptable flow-volume curves were obtained and the highest values of forced expiratory volume in 1 second (FEV1) and inspiratory vital capacity (IVC) were recorded. Airway resistance (RAW), specific airway resistance (SRAW), intrathoracic gas volume (ITGV), total lung capacity (TLC) and residual volume (RV) were also obtained.
CT examinations and scoring
As CF patients in this clinic are usually monitored by CT every 3 years we used the most recent high resolution CT scans obtained for routine follow-up within this period. Among the 21 CTs, 15 had been performed on the same day as the measurements or within the last 12 months (mean ± SD interval: 10 ± 10 months, range: 0–33 months).
Unenhanced low-dose CT examinations were performed on a clinical whole-body multidetector-row CT scanner (Mx 8000, Philips Medical Systems, Best, The Netherlands), with the patient in supine position, at 120 kV, 4 × 1 mm slice collimation, 3 mm reconstruction slice thickness, 10 mAs/slice (effective tube current-time product), and Pitch 1.75, resulting in an effective dose of approximately 0.5 mSv. Multiplanar image reformatting was performed in all instances, such that axial, coronal, and sagittal CT images were available for review on a picture archiving and communication system (PACS, "Impax", AGFA, Munich, Germany). CT images were evaluated by two independent experienced chest radiologists blinded to clinical or functional information, using a validated scoring system . The order in which CTs were scored was not randomized. In detail, scores for the presence and severity of parenchymal findings and airway disease were calculated of each lobe, with the lingula counted as a separate lobe. The following subscores were obtained by averaging subscores across the 6 lobes in each patient: bronchiectasis, mucous plugging, peribronchial thickening, and parenchymal disease. As expiratory scans were not available, the air trapping subscore was omitted. The scoring system has been described in detail by Brody at al. . In brief, the subscore for bronchiectasis (possible range: 0–12) was defined as the sum of the extent of bronchiectasis in the central lung (0–3) and in the peripheral lung (0–3), multiplied by the average bronchiectasis size (0–2). For the mucous plugging score (0–6) the extent of mucous plugging in the central lung (0–3) was added to the extent of mucous plugging in the peripheral lung (0–3). For the peribronchial thickening score (0–9) the sum of the extent of peribronchial thickening in the central lung (0–3) and the extent of peribronchial thickening in the peripheral lung (0–3) was multiplied by the severity of peribronchial thickening (1–1.5). The parenchyma score (0–9) was the sum of the extent of dense parenchymal opacity (0–3), the extent of ground glass opacity (0–3) and the extent of cysts or bullae (0–3). Subscores were added to obtain the total score, ranging between 0 and 36. The mean scores of both observers were used for analysis.
Median with range or mean values and standard deviations (SD) were computed. Z-scores were additionally calculated where appropriate using published equations [15–17, 21]. The relationship between functional measures and CT scores was quantified by Spearman's rank correlation (rS). Statistical comparisons were performed using the Wilcoxon test. Statistical significance was assumed for p < 0.05. To adjust the alpha level for multiple tests for correlation the Bonferroni method was used. All analyses were performed using SPSS 14.0 (SPSS Inc., Chicago, IL).
Basic characteristics and pulmonary function tests of 21 patients (females = 8; males = 13) with CF
35 ± 9
176 ± 11
65.5 ± 13.4
5.45 ± 1.78
87 ± 19
-1.3 ± 2.0
DLNO, mmol × min-1 × kPa-1
34.7 ± 12.2
71 ± 19
-2.3 ± 1.5
DLCO, mmol × min-1 × kPa-1
9.1 ± 2.7
83 ± 18
-1.3 ± 1.4
3.8 ± 0.4
KNO, mmol × min-1 × kPa-1 × L-1
6.34 ± 0.91
84.7 ± 11.9
-1.9 ± 1.6
KCO, mmol × min-1 × kPa-1 × L-1
1.69 ± 0.18
81.6 ± 7.4
-1.2 ± 0.6
Dm, mmol × min-1 × kPa-1
17.6 ± 6.2
80 ± 25
2.58 ± 1.35
66 ± 28
-2.7 ± 2.3
4.18 ± 1.56
88 ± 23
-1.1 ± 2.1
59 ± 13
73 ± 15
-3.2 ± 1.8
RAW, kPa × s × L-1
0.43 ± 0.25
SRAW, kPa × s
1.97 ± 1.24
4.14 ± 1.10
128 ± 27
1.6 ± 1.6
2.90 ± 1.06
162 ± 51
2.9 ± 2.5
7.08 ± 1.69
108 ± 15
0.8 ± 1.4
The median (range) total CT score in our sample was 10.7 (3.4–26.5). The corresponding subscore values were 3.9 (0.8–11.2) for bronchiectasis, 1.8 (0.6–4.5) for mucous plugging, 4.0 (0.8–8.7) for peribronchial thickening, and 1.3 (0.4–4.0) for the parenchyma subscore. The total CT scores correlated closely between the two observers, as indicated by the high intraclass correlation (ANOVA, R = 0.91), as well as the rank correlation coefficient (rS = 0.897; p < 0.001) and pairwise comparison according to Wilcoxon (p = 0.465). Subscores also significantly correlated between both observers (p < 0.001 each), despite differences in bronchiectasis and parenchyma subscores (Wilcoxon, p < 0.01 each).
Spearman rank coefficients between CT scores according to Brody et al.  and z-scores of lung function measures as obtained in bivariate analyses.
Overall CT Score
SRAW, kPa × s$
We found that in patients with CF, the correlation between DLNO as well as DLCO and CT was closer than for indices derived from spirometry and bodyplethysmography, including the standard measure for monitoring CF, FEV1. Additionally, using recently published reference values [17–19], DLNO %pred was significantly lower than DLCO %pred in CF.
At present, spirometry is the established standard in the assessment of patients with CF, while the role of DLCO is less well defined. This may be partially explained by the fact that diffusion measurements are influenced by a variety of functional or structural alterations in CF, e.g. the obstruction typically found in those patients, and thus difficult to interpret. In children with CF, DLCO has been shown to be stable despite a decline in FEV1 %pred , and in adults DLCO was found to decrease below reference values only in patients with severe disease . Based on these and other conflicting results [2, 22] it seems unlikely that DLCO is a useful marker of disease severity in CF.
In part, these differences may be due to the fact that DLCO essentially comprises two factors: the membrane (Dm) and the blood component (Vc). Changes of these two components do not necessarily correlate. In contrast to DLCO, DLNO is thought to mainly represent Dm, thus possibly better reflecting morphological alterations in CF. In our study sample values of DLNO%pred were regularly significantly lower than those for DLCO, using different reference equations [16–19]. This indicates that DLNO might be more sensitive for detecting CF-related structural changes of the lung. As different approaches were used to derive Dm and Vc by the authors of the recently published reference equations we did not compare our derived values with these references; further standardization of calculations seems desirable. In this study Dm was calculated as DLNO/1.97, whereas recently published data indicates that DLNO/2.42 may be more accurate . This however does not change correlations. Dm was more closely related with the CT score than Vc. As DLCO consists of Dm and Vc, the strong correlation with the CT score may be explained mainly by changes in Dm. The lower sensitivity to detect CF related changes expressed as percent of predicted values for DLCO compared to DLNO may be due to the additional influence of the pulmonary capillary blood volume, which is thought to be negligible when measuring DLNO. As DLNO is thought to be influenced by parenchymal alterations it may complement the standard parameter measuring obstruction, FEV1. CT is the standard measurement for structural alterations in CF, usually performed in intervals of several years. As the measurement of DLNO is non-invasive, easy to perform and closely correlated with the CT score, it may be applied more often during those routine visits when no CT scans are performed. However, prospective longitudinal studies are needed to decide whether the measurement of DLNO may provide additional value to the existing standard monitoring parameters.
As the reduction in diffusion capacities might be caused by a reduction in alveolar volume, which was also correlated with the CT score, we additionally assessed their values relative to alveolar volume. KCO was not related to the CT score or its subscores, while KNO decreased with increasing CT scores (figure 2), being specifically related to bronchiectasis, mucus plugging and peribronchial thickening. With decreasing VA, healthy subjects are known to show an increase in KCO indicating an increase in the thickness of the pulmonary capillary blood sheet , while KNO is essentially stable, reflecting the diffusional properties of the lung . Thus, both KCO and KNO reflect different aspects of lung morphology and functionality. In CF, VA and/or TLC may be reduced. This renders KNO, being less related to VA than KCO, superior for a noninvasive assessment of membrane diffusion, indicating structural alterations independent of volume-dependent effects. Our data strongly support this hypothesis. Zavorsky et al. recently published reference equations for DLNO using gender and age as well as either VA or height as predictors  to discern between patients with abnormal gas exchange or low lung volume. When using the equation including VA with our data mean ± SD predicted DLNO was 71 ± 13%, indicating abnormal gas exchange. The equation including height instead of VA resulted in a significantly lower predicted DLNO of 63 ± 18% (p < 0.001). According to these authors this means that a reduction in lung volume explains part of the low predicted DLNO. This is in line with the finding of a slightly reduced mean VA when expressed as percent of predicted. DLNO and DLCO also showed stronger correlations with the CT score than measures derived from spirometry and bodyplethysmography. It should be noted that a number of correlation coefficients were rather high, leading to only minor differences. Correlation coefficients were comparable or slightly lower when using absolute values instead of z-score values for DLNO and DLCO, probably reflecting the fact that lung function indices depend on anthropometric characteristics, in contrast to CT scores.
Among the subscores, the bronchiectasis score correlated best with most functional measures, similar to the total score. Indeed, bronchiectasis seems to be the most important structural change that can be reliably scored on CT . It has even been suggested that restricting scoring to bronchiectasis would suffice for CT monitoring in CF . It should be noted that most subscores reflect airway disease, whereas DLNO and KNO are influenced mainly by parenchymal destruction. Thus our findings show a good correlation between a CT score as a marker of disease severity and DLNO as a marker of parenchyma destruction. However, a causal connection between single subscores and the changes in diffusing capacities cannot be derived.
Thin-section CT represents the methodology of choice for the assessment of structural alterations in CF . For this purpose, a variety of disease-specific CT scores have been proposed  and it seems that further standardization of scores is mandatory. The CT scoring system used in our study has been demonstrated to be reproducible and sensitive to disease severity . CT scores are known to be subject to considerable interobserver variability, and the observation that for selected subscores the two experienced observers differed in their rating is in line with published data . In our study the differences concerned only the magnitude, while ratings were still correlated with each other.
Major weaknesses of this study are its retrospective nature and the time interval between scan and measurements of up to 3 years with a maximum interval of 1 year in 15 patients. Moreover, the order in which CTs were scored was not randomized. This short-coming may introduce additional bias concerning the CT scores.
Recent studies found an annual decline of total CT scores by -2.7% in subjects of an age range from 16 to 48 years , or of -1.0% in children and -1.5% in adults . One of those studies report a corresponding decline of FEV1 by 2.3%  in adults. The other found that the bronchiectasis score deteriorated faster than lung function parameters in children and adults . These findings suggest that the time interval of 3 years did not exert a major influence on our results. Furthermore, only patients with a fairly stable course of their disease were included in our study. It is, however, reasonable to expect even higher correlations with CT scores if these are performed at the same visit as the functional assessments.
In conclusion, our findings indicated that in patients with CF NO diffusing capacity was a functional measure that was suitable to quantify structural changes of the lung as assessed by CT scores. The suitability of NO diffusing capacity is in line with previous observations in healthy subjects or patients with other diseases than CF  and renders it a challenging question of whether the combined diffusing capacity for NO and CO has a potential to be included in the assessment of CF. In this respect, the conclusions of this retrospective cross-sectional study can only be limited. Future longitudinal studies have to decide over the potential of this method for the monitoring of CF patients.
The data represent part of the medical doctoral thesis of L. Filser.
- Keens TG, Mansell A, Krastins IR, Levison H, Bryan AC, Hyland RH, Zamel N: Evaluation of the single-breath diffusing capacity in asthma and cystic fibrosis. Chest. 1979, 76 (1): 41-44. 10.1378/chest.76.1.41.View ArticlePubMedGoogle Scholar
- Russell NJ, Bagg LR, Hughes DT, Neville E: Lung function in young adults with cystic fibrosis. Br J Dis Chest. 1982, 76 (1): 35-43. 10.1016/S0007-0971(82)80006-5.View ArticlePubMedGoogle Scholar
- Espiritu JD, Ruppel G, Shrestha Y, Kleinhenz ME: The diffusing capacity in adult cystic fibrosis. Respir Med. 2003, 97 (6): 606-611. 10.1053/rmed.2003.1487.View ArticlePubMedGoogle Scholar
- Merkus PJ, Govaere ES, Hop WH, Stam H, Tiddens HA, de Jongste JC: Preserved diffusion capacity in children with cystic fibrosis. Pediatr Pulmonol. 2004, 37 (1): 56-60. 10.1002/ppul.10357.View ArticlePubMedGoogle Scholar
- Chemery L, Fekete K, Guillot S, Roussey M, Desrues B, Dabadie A, Belleguic C, Deneuville E, Dassonville J: Diffusing capacity for carbon monoxide (T(LCO)) and oxygen saturation during exercise in patients with cystic fibrosis. Arch Pediatr. 2004, 11 (9): 1060-1066. 10.1016/j.arcped.2004.04.019.View ArticlePubMedGoogle Scholar
- de Jong PA, Lindblad A, Rubin L, Hop WC, de Jongste JC, Brink M, Tiddens HA: Progression of lung disease on computed tomography and pulmonary function tests in children and adults with cystic fibrosis. Thorax. 2006, 61 (1): 80-85. 10.1136/thx.2005.045146.View ArticlePubMedGoogle Scholar
- Borland CD, Higenbottam TW: A simultaneous single breath measurement of pulmonary diffusing capacity with nitric oxide and carbon monoxide. Eur Respir J. 1989, 2 (1): 56-63.PubMedGoogle Scholar
- MacIntyre N, Crapo RO, Viegi G, Johnson DC, Grinten van der CPM, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J: Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005, 26 (4): 720-735. 10.1183/09031936.05.00034905.View ArticlePubMedGoogle Scholar
- Guenard H, Varene N, Vaida P: Determination of lung capillary blood volume and membrane diffusing capacity in man by the measurements of NO and CO transfer. Respir Physiol. 1987, 70 (1): 113-120. 10.1016/S0034-5687(87)80036-1.View ArticlePubMedGoogle Scholar
- Rosenfeld M: An overview of endpoints for cystic fibrosis clinical trials: one size does not fit all. Proc Am Thorac Soc. 2007, 4 (4): 299-301. 10.1513/pats.200611-178HT.View ArticlePubMedGoogle Scholar
- Tiddens HA, de Jong PA: Imaging and clinical trials in cystic fibrosis. Proc Am Thorac Soc. 2007, 4 (4): 343-346. 10.1513/pats.200611-174HT.View ArticlePubMedGoogle Scholar
- de Jong PA, Tiddens HA: Cystic fibrosis specific computed tomography scoring. Proc Am Thorac Soc. 2007, 4 (4): 338-342. 10.1513/pats.200611-175HT.View ArticlePubMedGoogle Scholar
- Brody AS, Kosorok MR, Li Z, Broderick LS, Foster JL, Laxova A, Bandla H, Farrell PM: Reproducibility of a scoring system for computed tomography scanning in cystic fibrosis. J Thorac Imaging. 2006, 21 (1): 14-21. 10.1097/01.rti.0000203937.82276.ce.View ArticlePubMedGoogle Scholar
- Dressel H, Filser L, Fischer R, de la Motte D, Steinhaeusser W, Huber RM, Nowak D, Jörres RA: Lung diffusing capacity for nitric oxide and carbon monoxide: Dependence on breath-hold time. Chest. 2008, 133 (5): 1149-1154. 10.1378/chest.07-2388.View ArticlePubMedGoogle Scholar
- Frans A, Nemery B, Veriter C, Lacquet L, Francis C: Effect of alveolar volume on the interpretation of single breath DLCO. Respir Med. 1997, 91 (5): 263-273. 10.1016/S0954-6111(97)90029-9.View ArticlePubMedGoogle Scholar
- Cotes JE, Chinn DJ, Quanjer PH, Roca J, Yernault JC: Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 41-52.View ArticlePubMedGoogle Scholar
- Lee van der I, Zanen P, Stigter N, Bosch van den JM, Lammers JJ: Diffusing capacity for nitric oxide: reference values and dependence on alveolar volume. Respir Med. 2007, 101 (7): 1579-1584. 10.1016/j.rmed.2006.12.001.View ArticlePubMedGoogle Scholar
- Aguilaniu B, Maitre J, Glenet S, Gegout-Petit A, Guenard H: European reference equations for CO and NO lung transfer. Eur Respir J. 2008, 31: 1091-1097. 10.1183/09031936.00063207.View ArticlePubMedGoogle Scholar
- Zavorsky GS, Cao J, Murias JM: Reference values of pulmonary diffusing capacity for nitric oxide in an adult population. Nitric Oxide. 2008, 18: 70-79. 10.1016/j.niox.2007.10.002.View ArticlePubMedGoogle Scholar
- Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, Grinten van der CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J: Standardisation of spirometry. Eur Respir J. 2005, 26 (2): 319-338. 10.1183/09031936.05.00034805.View ArticlePubMedGoogle Scholar
- Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl. 1993, 16: 5-40.View ArticlePubMedGoogle Scholar
- Cotton DJ, Graham BL, Mink JT, Habbick BF: Reduction of the single breath CO diffusing capacity in cystic fibrosis. Chest. 1985, 87 (2): 217-222. 10.1378/chest.87.2.217.View ArticlePubMedGoogle Scholar
- Glénet SN, De Bisschop C, Vargas F, Guénard HJP: Deciphering the nitric oxide to carbon monoxide lung transfer ratio: physiological implications. J Physiol. 2007, 582 (2): 767-775. 10.1113/jphysiol.2007.133405.View ArticlePubMedPubMed CentralGoogle Scholar
- Judge EP, Dodd JD, Masterson JB, Gallagher CG: Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. Chest. 2006, 130 (5): 1424-1432. 10.1378/chest.130.5.1424.View ArticlePubMedGoogle Scholar
- Lee van der I, Zanen P, Grutters JC, Snijder RJ, Bosch van den JM: Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension. Chest. 2006, 129 (2): 378-383. 10.1378/chest.129.2.300.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2466/9/30/prepub